Orgenesis Inc.

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:44:03 2024-05-17 pm EDT			5-day change	1st Jan Change
0.537 ^USD	+1.13%		-3.22%	+12.10%

Apr. 16	North American Morning Briefing : Powell Comments, -2-	DJ
Apr. 15	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.

March 22, 2023 at 05:25 pm EDT

From October 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 367,896 shares, representing 1.53% for $1.6 million under the buyback announced on May 15, 2020.

Latest news about Orgenesis Inc.

North American Morning Briefing : Powell Comments, -2-	Apr. 16	DJ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	Apr. 10	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Orgenesis Inc. announced that it has received $2.340901 million in funding	Mar. 04	CI
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	Mar. 02	CI
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	Jan. 30	CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	Jan. 23	CI
Alimera Sciences Appoints New CFO	Jan. 02	MT
Earnings Flash (ORGS) ORGENESIS Reports Q3 Revenue $110,000	Nov. 13	MT
Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	Nov. 08	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	Nov. 08	MT
Orgenesis Prices $1.1 Million Registered Direct Offering	Nov. 08	MT
Orgenesis Inc. announced that it expects to receive $1.1 million in funding	Nov. 07	CI
Orgenesis Scraps Planned Public Offering of Units Due to Market Conditions	23-10-31	MT
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States	23-09-21	CI
Orgenesis Inc. announced that it has received $1 million in funding	23-08-30	CI
Transcript : Orgenesis Inc., Q2 2023 Earnings Call, Aug 11, 2023	23-08-11
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	23-08-10	CI
Orgenesis Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart Orgenesis Inc.

Duration

Period

More charts

Company Profile

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâs therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâs services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ORGENESIS INC.	+12.10%	18.08M
ABBOTT LABORATORIES	-5.50%	182B
MEDTRONIC PLC	+4.41%	114B
BECTON, DICKINSON AND COMPANY	-3.25%	68.38B
DEXCOM, INC.	+5.58%	52.46B
CENCORA, INC.	+8.10%	44.25B
HOYA CORPORATION	+7.52%	43.55B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.14%	32.69B
TERUMO CORPORATION	+17.85%	26.73B
WEST PHARMACEUTICAL SERVICES, INC.	+0.59%	25.79B

Other Medical Equipment, Supplies & Distribution

Orgenesis Inc.

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.

Latest news about Orgenesis Inc.

Chart Orgenesis Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution